EN DE
Watch Shilpa Medicare Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Shilpa Medicare Limited (SHILPAMED) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Shilpa Medicare Limited stock ₹252, price ₹938, that is 73.2% below the price, quality 50 out of 100. Rating: strongly overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE790G01031

SM Shilpa Medicare Limited logo Broad data Nov 12, 2026

Shilpa Medicare Limited

SHILPAMED · NSE

Far too expensive (fair value 73% below the price) and company just short of the bar, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Solidly profitable · 18.0% net margin (TTM) 
Low debt 
Broad data 
Last quarter vs. a year ago: revenue +45%, profit +80%. 
Quality 50/100 
Expensive Growth (revenue 5y +11.3 %/yr in INR) 
0.1% dividend yield · Token dividend
Mixed vs. peers (6/13) 
Moderate moat 62/100 · thin data
Fair value ₹251.84 · Strongly overvalued 
Negative free cash flow 
Watch Shilpa Medicare Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹1,076 ₹114.14 Fair Value ₹251.84 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.

How to read this chart

60‑month range ₹114.14 – ₹1,076 · fair‑value band ₹176.29 – ₹327.39 · the ₹938.35 price screens above the ₹251.84 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 12, 2026.

Follow Shilpa Medicare in your weekly email

Every Wednesday you see whether Shilpa Medicare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally.

Show moreShow less

The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. It also provides nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate.

In addition, the company offers intermediates; peptides; biopolymers; biologics; contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, dry powder injectable products, oral dissolving films, transdermal patches.

Further, it is involved in the manufacture of specialized oncology formulations; and wind power generation activities. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003.

Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.

Stock analysis

Shilpa Medicare Limited (SHILPAMED) currently trades at ₹938.35, while our model-based Fair Value estimate is ₹251.84, 73% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of ₹258.04 per share, and 0 of the 16 models we run sit above the ₹938.35 price.

Bear case: the Asset-Based group reads lowest at ₹64.96, and 16 of the 16 models stay below the price. Data coverage for this calculation is high.

Scenario range: ₹176.29 (bear) to ₹327.39 (bull), the price of ₹938.35 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Shilpa Medicare Limited reported revenue of ₹15.4B in FY2026 versus ₹11.4B in FY2022, a compound +7.8%/yr. Reported net income was ₹2.4B in FY2026, compounding +41.5%/yr from FY2022.

Key figures

Market cap ₹184B (≈ $1.9B) Mid · P/E ratio 54.9 · P/S ratio 8.69 · EPS (TTM) ₹17.08 · Dividend yield 0.1% · Net margin 15.8% · Return on equity 12.8% · Return on assets (EBIT) 6.2% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 62 out of 100 (low confidence).

What moves the price

The share trades about 13% below its 52-week high and 252% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −73%, SHILPAMED screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (₹5.61 to ₹436.27). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ₹176.29 Fair Value ₹251.84 Bull ₹327.39
Price ₹938.35 · Downside -73.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹10.38 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income ₹103.16 ₹107.42 ₹121.05 76
EPV ₹90.00 ₹101.79 ₹111.39 74
ROIC Compounder ₹90.00 ₹101.79 ₹111.39 72
All 16 models by family
Earnings-Based
Graham-Dodd ₹84.60 ₹414.09 ₹570.71 64
Lynch FV ₹113.89 ₹162.70 ₹211.51 61
PEG = 1.0 ₹113.89 ₹162.70 ₹211.51 57
EPV ₹90.00 ₹101.79 ₹111.39 74
Dividend Discount
Gordon GGM ₹3.52 ₹5.93 ₹7.74 68
DDM Multi-Stage ₹3.52 ₹5.61 ₹6.38 67
Multiples
P/E Multiple ₹205.28 ₹273.71 ₹342.14 63
P/S Multiple ₹158.63 ₹211.50 ₹264.38 58
P/B Multiple ₹327.20 ₹436.27 ₹545.33 55
EV/EBIT ₹173.91 ₹242.36 ₹310.81 66
EV/EBITDA ₹201.95 ₹279.74 ₹357.54 67
EV/Revenue ₹115.13 ₹177.94 ₹240.75 53
Asset-Based
NCAV (Graham) ₹48.47 ₹64.96 ₹96.95 54
Economic Profit
Residual Income ₹103.16 ₹107.42 ₹121.05 76
ROIC Compounder ₹90.00 ₹101.79 ₹111.39 72
Growth Earnings
Growth-Adj P/E ₹176.29 ₹251.84 ₹327.39 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 50/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 43
How much profit the company makes from its sales and capital
Quality Growth 66
Are margins and returns getting better?
Cashflow 29
Do the profits arrive as real cash?
Financial strength 64
Debt, balance sheet and risk of trouble
Investment 31
Does it invest with discipline instead of growing at any price?
Low Volatility 67
How calm the share price moves, does not count
Price momentum 89
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 92
Distance to the 52-week high, does not count
New shares 58
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 56/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+19.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.3%
Start year 2021 (pandemic). Over 10 years: +9.2% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.0%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +8.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+8.7%
Dividend (yield on the price)0.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5.4% vs 6.0%, steady
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 21%
Pace: the 5-year rate starts in 2021 (pandemic)
⚠ Rate on operating basis: 2026 sits 325% above its own trend.

SHILPAMED screens overvalued: fair value 73% below the price. Compare with Merck KGaA →

Compare Shilpa Medicare Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 50 · Below median
Fair Value upside −74.6% · Bottom 25%
Profitability
Return on equity (12 months) 12.8% · Above median
Return on assets 6.6% · Above median
Net margin (12 months) 18.0% · Top 25%
Operating margin (12 months) 21.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 45.4% · Top 25%
Dividend yield (12 months) 0.1% · Bottom 25%
Balance sheet
Debt / equity 0.07× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 54.9× · Priciest 25%
P/B 7.48× · Priciest 25%
P/S (12 months) 10.50× · Priciest 25%
EV/EBITDA 42.3× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 17
FUTURE (revenue growth)100 · sector 29
PAST (return on equity)51 · sector 26
HEALTH (low debt)96 · sector 96
DIVIDEND (yield)1 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Shilpa Medicare Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Shilpa Medicare Limited Fair Value". https://www.fairvalue-calculator.com/stock/SHILPAMED

Frequently asked questions

Is Shilpa Medicare Limited (SHILPAMED) overvalued or undervalued?
As of Nov 12, 2026, our model estimates a fair value of ₹251.84 versus a price of ₹938.35, about 73% lower (overvalued).
What is the fair value of SHILPAMED?
Our model-based fair value for Shilpa Medicare Limited is ₹251.84 (as of Nov 12, 2026), built from audited fundamentals. The current price: ₹938.35.
What is the quality score of SHILPAMED?
Shilpa Medicare Limited has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shilpa Medicare Limited (SHILPAMED)?
Our model-based price target is the fair value of ₹251.84 (as of Nov 12, 2026) from 16 valuation models. Cautious scenario ₹176.29, optimistic scenario ₹327.39. It is a calculation from audited fundamentals, not an analyst target.
What is the Shilpa Medicare Limited stock forecast for 2026?
Our models put fair value at ₹251.84, about 73% lower versus a price of ₹938.35 (overvalued). Cautious scenario ₹176.29, optimistic scenario ₹327.39. The calculation is refreshed regularly with new filings.
What is the revenue of Shilpa Medicare Limited (SHILPAMED)?
Shilpa Medicare Limited reported trailing-twelve-month revenue of about ₹18.5B (latest available figure, as of Nov 12, 2026).
Does Shilpa Medicare Limited pay a dividend?
Shilpa Medicare Limited currently shows a dividend yield of 0.06% relative to its recent price (as of Nov 12, 2026).
How much is the dividend of Shilpa Medicare Limited (SHILPAMED) and when is the ex-dividend date?
Shilpa Medicare Limited pays a dividend of ₹0.6 per share a year, a dividend yield of 0.1%. The last ex-dividend date was Sep 4, 2026. The payout ratio is 3.5% of earnings. Our assessment: Token dividend. At a yield of 0.1% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.1% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Shilpa Medicare Limited (SHILPAMED)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shilpa Medicare Limited it is ₹251.84 per share (as of Nov 12, 2026), against a price of ₹938.35. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Shilpa Medicare Limited stock overvalued or undervalued in 2026?
As of Nov 12, 2026, SHILPAMED trades above its calculated fair value: price ₹938.35, fair value ₹251.84, a gap of about −73% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SHILPAMED?
No. The price is what the market pays today (₹938.35); the fair value is what the company's own numbers justify (₹251.84). For Shilpa Medicare Limited the two are ₹686.51 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shilpa Medicare Limited worth?
The market values Shilpa Medicare Limited at about ₹184B (market capitalisation, as of Nov 12, 2026). Per share that is ₹938.35; our models calculate a fair value of ₹251.84 per share.
What do the bullish and bearish scenarios say about SHILPAMED?
Our models span a range for Shilpa Medicare Limited: cautious scenario ₹176.29, base ₹251.84, optimistic ₹327.39 per share (as of Nov 12, 2026, price ₹938.35). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SHILPAMED?
Shilpa Medicare Limited trades at a price-to-earnings ratio of 54.9 (as of Nov 12, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹251.84 is built from several models across several years. Other multiples: P/B 7.5, P/S 10.5, EV/EBITDA 42.3.
How solid is the balance sheet of Shilpa Medicare Limited (SHILPAMED)?
Balance-sheet figures for Shilpa Medicare Limited (as of Nov 12, 2026): return on equity 12.8%, debt of 0.07 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is SHILPAMED from its 52-week high?
Shilpa Medicare Limited trades at ₹938.35, about 13% below its 52-week high of ₹1,076 and 252% above the low of ₹266.83 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹251.84 is for.
Which stocks are comparable to Shilpa Medicare Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Galderma Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shilpa Medicare Limited stock attractive at the current price?
The data as of Nov 12, 2026: price ₹938.35, calculated fair value ₹251.84 (−73%), Quality Score 50/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SHILPAMED calculated?
We run Shilpa Medicare Limited through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹251.84 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Shilpa Medicare Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shilpa Medicare Limited (SHILPAMED)?
The closing price on Nov 16, 2026 was ₹938.35. Our model-based fair value is ₹251.84, about 73% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shilpa Medicare Limited right now?
The price sits above even our optimistic bull case (₹327.39). The favourable scenario is already priced in. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹176.29 to ₹327.39) leaves room in how you read the outcome.
Where does the earnings growth of Shilpa Medicare Limited (SHILPAMED) come from?
Earnings per share at Shilpa Medicare Limited fell 1.9 % a year from 2015 to 2026. Broken into its drivers: revenue per share +3.6 %, EBIT margin +1.8 %, tax rate +0.4 %, residual (interest, one-offs) −7.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Shilpa Medicare Limited

How large is the market capitalisation of Shilpa Medicare Limited (SHILPAMED)?
The market capitalisation of Shilpa Medicare Limited is ₹184B (≈ $1.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shilpa Medicare Limited (SHILPAMED)?
The price-to-sales ratio of Shilpa Medicare Limited is 8.69 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shilpa Medicare Limited (SHILPAMED)?
Earnings per share at Shilpa Medicare Limited are ₹17.08 (price ÷ EPS = P/E 54.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shilpa Medicare Limited (SHILPAMED)?
The dividend yield of Shilpa Medicare Limited is 0.1% (payout 3.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shilpa Medicare Limited (SHILPAMED)?
The net margin of Shilpa Medicare Limited is 15.8% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shilpa Medicare Limited (SHILPAMED)?
The return on equity (ROE) of Shilpa Medicare Limited is 12.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shilpa Medicare Limited (SHILPAMED)?
On an EBIT basis the return on assets of Shilpa Medicare Limited is 6.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shilpa Medicare Limited (SHILPAMED)?
The operating margin of Shilpa Medicare Limited is 21.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shilpa Medicare Limited (SHILPAMED)?
Revenue at Shilpa Medicare Limited is growing 45.4% versus a year earlier (3y avg +13.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shilpa Medicare Limited (SHILPAMED)?
Earnings per share at Shilpa Medicare Limited are growing 80.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Shilpa Medicare Limited (SHILPAMED) generate?
The free cash flow of Shilpa Medicare Limited is −₹754M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Shilpa Medicare Limited (SHILPAMED) carry?
The net debt of Shilpa Medicare Limited is ₹6.1B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Shilpa Medicare Limited in the live analysis

One click puts Shilpa Medicare Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.